JP2022526979A5 - - Google Patents

Info

Publication number
JP2022526979A5
JP2022526979A5 JP2021559100A JP2021559100A JP2022526979A5 JP 2022526979 A5 JP2022526979 A5 JP 2022526979A5 JP 2021559100 A JP2021559100 A JP 2021559100A JP 2021559100 A JP2021559100 A JP 2021559100A JP 2022526979 A5 JP2022526979 A5 JP 2022526979A5
Authority
JP
Japan
Prior art keywords
represented
bifunctional compound
pharmaceutically acceptable
stereoisomer
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021559100A
Other languages
English (en)
Japanese (ja)
Other versions
JP7667742B2 (ja
JP2022526979A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/027236 external-priority patent/WO2020210337A1/en
Publication of JP2022526979A publication Critical patent/JP2022526979A/ja
Publication of JP2022526979A5 publication Critical patent/JP2022526979A5/ja
Application granted granted Critical
Publication of JP7667742B2 publication Critical patent/JP7667742B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021559100A 2019-04-09 2020-04-08 Atp競合性akt阻害剤gdc-0068とe3リガーゼリガンドとの結合によるaktの分解および使用方法 Active JP7667742B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962831267P 2019-04-09 2019-04-09
US62/831,267 2019-04-09
PCT/US2020/027236 WO2020210337A1 (en) 2019-04-09 2020-04-08 Degradation of akt by conjugation of atp-competitive akt inhibitor gdc-0068 with e3 ligase ligands and methods of use

Publications (3)

Publication Number Publication Date
JP2022526979A JP2022526979A (ja) 2022-05-27
JP2022526979A5 true JP2022526979A5 (cg-RX-API-DMAC7.html) 2023-04-14
JP7667742B2 JP7667742B2 (ja) 2025-04-23

Family

ID=72750645

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021559100A Active JP7667742B2 (ja) 2019-04-09 2020-04-08 Atp競合性akt阻害剤gdc-0068とe3リガーゼリガンドとの結合によるaktの分解および使用方法

Country Status (7)

Country Link
US (1) US12642857B2 (cg-RX-API-DMAC7.html)
EP (1) EP3952871A4 (cg-RX-API-DMAC7.html)
JP (1) JP7667742B2 (cg-RX-API-DMAC7.html)
CN (1) CN113645972A (cg-RX-API-DMAC7.html)
AU (1) AU2020270908B2 (cg-RX-API-DMAC7.html)
CA (1) CA3134491A1 (cg-RX-API-DMAC7.html)
WO (1) WO2020210337A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114478534B (zh) * 2020-10-24 2025-08-05 杭州中美华东制药有限公司 具有抗肿瘤活性的嵌合分子及其制备方法和应用
WO2024146599A1 (zh) * 2023-01-06 2024-07-11 南京正大天晴制药有限公司 一种二氢吡啶并[2,3-d]嘧啶酮的衍生物、其制备方法以及医药用途
CN120157686A (zh) * 2023-12-14 2025-06-17 南京正大天晴制药有限公司 一种具有降解akt激酶活性的化合物及其制备方法和药学上的应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
EP4649963A3 (en) 2014-04-14 2026-05-13 Arvinas Operations, Inc. Imide-based modulators of proteolysis and associated methods of use
IL325256A (en) 2014-06-13 2026-02-01 Bach Biosciences Llc FAP-activated medical materials and related uses
WO2017185031A1 (en) 2016-04-22 2017-10-26 Dana-Farber Cancer Institute, Inc. Degradation of cyclin-dependent kinase 4/6 (cdk4/6) by conjugation of cdk4/6 inhibitors with e3 ligase ligand and methods of use
CN109562107A (zh) * 2016-05-10 2019-04-02 C4医药公司 用于靶蛋白降解的杂环降解决定子体
JP2021515013A (ja) * 2018-03-06 2021-06-17 アイカーン スクール オブ メディスン アット マウント シナイ セリンスレオニンキナーゼ(akt)分解/破壊化合物および使用方法

Similar Documents

Publication Publication Date Title
CN1250293C (zh) 药物复合物
JP2015534578A5 (cg-RX-API-DMAC7.html)
JP2016502504A5 (cg-RX-API-DMAC7.html)
JP2015534580A5 (cg-RX-API-DMAC7.html)
JP2018537975A5 (cg-RX-API-DMAC7.html)
JP2021100937A5 (cg-RX-API-DMAC7.html)
JP2013100314A5 (cg-RX-API-DMAC7.html)
JP2020500862A5 (cg-RX-API-DMAC7.html)
JP2022512900A5 (cg-RX-API-DMAC7.html)
JP2020506951A5 (cg-RX-API-DMAC7.html)
EA201270738A1 (ru) Модуляторы фармакокинетических свойств лекарственных средств
JP2021519076A5 (cg-RX-API-DMAC7.html)
JP2004525170A (ja) Has−活性成分コンジュゲート
JPWO2020031936A5 (cg-RX-API-DMAC7.html)
JP2020097577A5 (cg-RX-API-DMAC7.html)
JP2015518825A5 (cg-RX-API-DMAC7.html)
RU2351330C2 (ru) Применение эпотилонов в лечении заболеваний головного мозга, ассоциированных с пролиферативными процессами
JP6957629B2 (ja) 非線状自壊性リンカーおよびそのコンジュゲート
JP2004533444A5 (cg-RX-API-DMAC7.html)
JP2007509978A5 (cg-RX-API-DMAC7.html)
JP2017526677A5 (cg-RX-API-DMAC7.html)
JP2009501800A5 (cg-RX-API-DMAC7.html)
CN104530417A (zh) 一种多官能化h型聚乙二醇衍生物及其制备方法
JP2012518029A5 (cg-RX-API-DMAC7.html)
AR056155A1 (es) Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica